Objectives: To determine the prevalence of hepatitis C virus (HCV) infection in patients with B-cell non-Hodgkin's lymphoma (NHL) in British Columbia.
Introduction
Over the past decade, there has been an increasing awareness that chronic infection with the hepatitis C virus (HCV) is associated with significant extra-hepatic manifestations. Many of these systemic manifestations of HCV are immunologically-mediated and include the production of various autoantibodies [1] and the multiorgan effects of essential mixed cryoglobulinemia [2] [3] [4] . HCV has also been demonstrated to possess lymphotropic effects, in addition to its known hepatotrophism, as HCV-RNA can be detected in the peripheral blood mononuclear cells of patients with chronic HCV [5] . It has been postulated that the persistence of HCV may chronically stimulate B-lymphocytes [6] , leading to clonal expansion and eventual malignant B-cell lymphoproliferative disorders. The hypothesis, formulated in the years before the characterization of the hepatitis C virus, that essential mixed cryoglogulinemia was a possible variant of low grade B-cell non-Hodgkin's lymphoma (NHL) [7] and the now accepted association of HCV in the pathogenesis of essential mixed cryoglobulinemia, has led to the hypothesis that HCV may also be causally linked to B-cell NHLs. Several studies from Italy [8] [9] [10] [11] [12] [13] [14] , Japan [15] [16] and in the United States (Los Angeles, California) [17] have reported a significantly higher prevalence of HCV in patients with B-cell NHL. On the other hand, several centers in the United Kingdom [18] [19] [20] , Germany [21] , The Netherlands [22] , a different region in the United States (Columbia, Missouri) [23] and one in Canada [28] have failed to find an increased prevalence of HCV in B-cell NHL suggesting a possible geographic variation.
Because of the paucity of Canadian studies and the apparent differences between international centers regarding an association between HCV and B-cell NHL, we sought to examine our data to determine if an association between the two conditions exists in British Columbia (BC), Canada. Since a positive association has not been seen in patients with T-cell NHL, these patients constitute an appropriate control group.
Patients and methods

Lymphoma patients
The lymphoma database of the British Columbia Cancer Agency (BCCA) was examined. The BCCA is a Canadian provincial tertiary oncology referral center for the province of BC and its Vancouver center is a teaching hospital of the University of British Columbia. Data on all newly referred patients with a diagnosis of lymphoma are entered into a computerized database. The specific diagnosis of lymphoma is made on the basis of the morphologic features of lymph node tissue and extra-nodal biopsies including bone marrow specimens. Immunophenotypic analysis of B-and T-lymphocytic markers are performed with appropriate monoclonal antibodies using either flow cytometric assessment for immunostains or paraffin sections. The database records patient information including age, sex, date of diagnosis, HIV status, stage, histopathology and immunophenotype. Serum samples were collected prospectively on the majority of newly diagnosed patents, frozen and stored at the Vancouver center of the BCCA.
Control patients
The control data consisted of patient information obtained from the records of the Red Cross of BC (unpublished data, Dr David Pi, Medical Director Red Cross of BC). The Red Cross records the baseline anti-HCV serology from health-care workers presenting after a needle-stick injury. We used the records for individuals seen for such an injury between 1992-1993 to serve as a baseline from a normal population.
Study design
A cross-sectional design was employed comparing the prevalence of HCV infection in three patient groups: patients with B-cell NHL, patients with T-cell NHL and a second control group from the general population. The B-cell NHL group consisted of all patients entered into the lymphoma database in the calendar year 1996 and early 1997 for whom stored serum was available for determination of HCV infection. The T-cell NHL group consisted of all patients in the calendar years 1995-1997 inclusive, for whom stored serum was available for determination of HCV infection. The calendar years 1995-1997 were chosen for the T-cell NHL group in order to achieve adequate patient numbers for comparison because of the lesser incidence of T-cell NHL (compared to B-cell NHL) in BC. Patients with HIV seropositivity were excluded from the analysis. Although the lymphoma database does not record racial demographic information, an attempt was made to determine the racial composition of the two groups using patient surname. Because of the limitations using this method, a descriptive analysis was used to describe racial characteristics.
Assessment of HCV infection
Thawed aliquots of all stored serum samples were tested for antibodies against HCV with a third generation enzyme-linked immunosorbent assay (EIA) (Ax Sym, Abbott, Chicago, IL). Samples found to be seropositive with this assay were further analyzed with two confirmatory EIA tests (UBI HCV 4.0, Organon Tecknika, Scarborough, ON; and RIBA, Ortho-Clinical Diagnostic, Peterborough, ON). Samples positive on all three assays were confirmed by reverse transcriptase polymerase chain reaction (PCR) (Amplicor, Hoffman LaRoche, Branchburg, NJ).
Statistical analysis
It was determined a priori that a sample size of 58 patients in both the study and control groups was needed for the analysis to have an alpha level of significance of 0.05 and a beta error of 0.20. This was calculated using an estimated prevalence of HCV in the control group of 2% and assuming that the prevalence of HCV in the treatment group was 15% or greater. Comparisons between the study and control groups were performed using the binomial distribution. The statistical computer software used for the analysis was SPLUS. An alpha level of significance was set at 0.05. Abbreviations: MALT -mucosa associated lymphoid tissue; NOS not otherwise specified.
Results
Data on 205 patients with B-cell NHL were entered into the lymphoma database in 1996 and early 1997. Of these patients, stored sera were available for determination of HCV status in 88. Similarly, data on 91 patients were recorded with T-cell NHL from 1995 to 1997. Stored sera were available for determination of HCV status in 37 patients from the T-cell NHL study group. The other control group consisted of 1085 health-care workers.
The demographic characteristics of the patients are summarized in Table 1 . The median age of patients with B-cell NHL was 61.5 years (range: 23-86 years). The median age of patients with T-cell NHL was 56 years (range: 20-82 years). Fifty-one percent of the patients in the B-cell NHL group, and fifty-nine percent of the T-cell NHL group patients were male. The majority of patients in both groups were identified as Caucasian (by surname). Twelve percent (w = 11) in the B-cell NHL group, and nineteen percent (n -7) in the T-cell NHL group were identified as South-East Asian. No demographic characteristics of the control group representing the general population were available. The distribution of histological subtypes of B-cell NHL found in this study are identified in Table 2 .
The prevalences of HCV infection in the three groups are summarized in Table 3 . In the B-cell NHL group, 2 of the 88 patients were found to be anti-HCV seropositive (2.3%). In the T-cell NHL group, none of the 37 in the group was found to be anti-HCV seropositive. Eleven of 1085 health-care workers were found to be anti-HCV seropositive (1%). The seroprevalence of HCV in the B-cell NHL group does not statistically differ from either control group. Two patients in the B-cell NHL group were found to have chronic HCV infection. The first was a 71-year-old South-East Asian female with stage IIAE bulky diffuse large-cell disease of the larynx and thyroid. This patient was treated with doxorubicin-based multiagent chemotherapy and has no evidence of disease after 24 months of follow-up. The second patient was a 58-year-old Caucasian female with a stage IVA gastric mucosa associated lymphoid tissue lymphoma (MALToma). Her treatment consisted of anti-Helicobacter pylori antibiotics.
Discussion
Over the past few years there has been much speculation and debate about the exact role of HCV in the pathogenesis of B-cell NHL. Many studies from centers in Italy [8] [9] [10] [11] [12] [13] [14] and Japan [15, 16] have reported a significantly higher prevalence of chronic HCV in patients with B-cell NHL as compared with control groups more representative of the general population. Recently, Silvestri [24] combined the data of 21 published studies and found the overall prevalence of HCV in association with B-cell NHL to be 19%. The positive association found in these studies, however, must be balanced by the lack of association reported in the United Kingdom [18] [19] [20] , Western Europe [21, 22] and Toronto, Canada [28] . Within the United States, varying degrees of association have also been noted, with a strong association noted from one center in Los Angeles [17] but no association reported in Missouri [23] . The reasons for this highly variable pattern of association are not clear. It has been speculated that there may be regional differences and geographic associations. We speculate that the reasons for the apparent geographic variation may be in part environmental, but that a possible racial interaction between HCV and lymphoproliferation may also exist. This may explain the variable association within the United States, which is a racially heterogeneous society with distinct regional demographics. For instance, Zuckerman et al reported a prevalence of HCV in association with B-cell NHL of 22% from a Los Angeles center for which the patient population was 78% Hispanic and only 6% non-Hispanic Caucasian [17] . Within the same city, but at a center which had a patient population that was only 25% Hispanic and African-American, Kashyap et al., reported a HCV prevalence of only 11.5% amongst those with B-cell NHL [25] .
We examined the prevalence of HCV in patients with B-cell NHL and compared them to two control groups: patients with T-cell NHL and health care workers. The two lymphoma groups had similar demographics. Although serum samples were not available for many patients in both of the lymphoma groups, it is likely that the omission of an extra tube of serum for storage at the time of the patient encounter was a random event and not the result of any systematic selection process. The extra serum samples obtained were not designated for any purpose other than 'research' and took place before we conceived of this project and began testing for the presence of HCV. Therefore, the stored sera are most likely representative of lymphoma patients in British Columbia. Furthermore the distribution of histological subtypes found in our patients (Table 2) is consistent with the known distribution of B-cell NHL suggesting that our NHL population is similar to NHL patients elsewhere in terms of lymphoma subtypes. The absence of HCV infection in the T-cell NHL group is consistent with the lack of association of HCV and T-cell NHL noted in all previous studies [24] . Similarly, the finding of a 1% prevalence of HCV in our control group of health-care workers is consistent with other data collected by the Red Cross of BC in which the prevalence of HCV in first-time blood donors was found to be 0.7% between 1995-1997 (unpublished data, Dr David Pi, Red Cross). These data may underestimate the true prevalence of HCV in the general population as younger people, females and healthy volunteers would be expected to have a lower seroprevalence than the population at large. An underestimate of HCV seroprevalence in this group would bias toward an exaggerated difference between it and the B-cell NHL group. This was not found in our study.
The lack of a significant association between HCV infection and B-cell NHL in British Columbia supports the general hypothesis that this association is regional in nature and that a racial predisposition may exist. The majority of patients with B-cell NHL in our study were Caucasian. In BC, the vast majority of Caucasians are of British /Western European descent and it appears plausible that our findings would be similar to those reported in the United Kingdom and Western Europe. The two countries which have reported a strong association between HCV and B-cell NHL, are Italy and Japan. Only 3% and 0.9% of BC residents have ethnic origins from these nations respectively (source: Statistics Canada, 1996 Canadian Census).
Another hypothesis to explain the regional variation in association of HCV and B-cell NHL is that different HCV genotypes may have different degrees of lymphotropism or different oncogenic potential. It is known that certain HCV genotypes are associated with certain extra-hepatic non-malignant manifestations. There may also be associated genotypes of HCV infection which are more commonly associated with B-cell NHL. Data from Italy have found that HCV genotypes 2a and 2b are the ones most commonly associated with B-cell NHL [26, 29] . In British Columbia, 3 HCV genotypes have been isolated (types 1, 2, and 3) with subtypes lc and lb most common [27] .
In conclusion, although chronic HCV infection may be a risk factor for B-cell NHL in certain populations or with certain genotypes of the virus, there does not appear to be a significant association in British Columbia. Given the results of these data, we do not recommend routine testing of HCV in newly diagnosed lymphoma patients. Future investigations of the association of B-cell lymphoma and HCV should include characterization of the viral genotype to determine if different strains have differing lymphotrophism and transforming potential.
